Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)

Introduction: Tregs infiltrate tumors and inhibit immune responses against them. Methods: We investigated subpopulations of Foxp3+ CD4 T cells previously defined by Miyara et al. (Immunity 30, 899–911, 2009) in peripheral blood mononuclear cells (PBMCs) and tumor infiltrating lymphocytes (TILs) in lung cancer. We also showed that Tregs in healthy donors that express CCR4 could be efficiently eliminated in vitro by cotreatment with antihuman (h) CCR4 mAb (KM2760) and NK cells. Results: In lung cancer, the number of activated/effector Tregs and non-Tregs, but not resting/naive Tregs, was increased in TILs compared with the number of those cells in PBMCs. The non-Treg population contained Th2 and Th17. CCR4 expression on activated/effector Tregs and non-Tregs in TILs was down-regulated compared with that on those cells in PBMCs. Chemokinetic migration of CD25+ CD4 T cells containing the Treg population sorted from the PBMCs of healthy donors to CCL22/MDC was abrogated by pretreatment with anti-hCCR4 mAb (KM2760). The inhibitory activity of CD25+ CD127dim/− CD4 Tregs on the proliferative response of CD4 and CD8 T cells stimulated with anti-CD3/CD28 coated beads was abrogated by adding an anti-hCCR4 mAb (KM2760) and CD56+ NK cells to the culture. Conclusions: The findings suggested the CCR4 on activated/effector Tregs and non-Tregs was functionally involved in the chemokinetic migration and accumulation of those cells to the tumor site. In vitro findings of efficient elimination of Tregs may give the basis for implementation of a clinical trial to investigate Treg depletion by administration of an anti-hCCR4 mAb to solid cancer patients.

[1]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy , 2016, Cell Research.

[2]  M. Caetano,et al.  T helper 17 cells play a critical pathogenic role in lung cancer , 2014, Proceedings of the National Academy of Sciences.

[3]  A. Yamauchi,et al.  Systematic single cell analysis of migration and morphological changes of human neutrophils over stimulus concentration gradients. , 2014, Journal of immunological methods.

[4]  J. Karbach,et al.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.

[5]  Takeshi Takahashi,et al.  Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma , 2013, International journal of cancer.

[6]  A. DeMichele,et al.  CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients , 2012, Science Translational Medicine.

[7]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[8]  R. Ueda,et al.  Antibody therapy for Adult T-cell leukemia–lymphoma , 2011, International journal of hematology.

[9]  Qifeng Yang,et al.  Aberrant expression of chemokine receptor CCR4 in human gastric cancer contributes to tumor‐induced immunosuppression , 2011, Cancer science.

[10]  T. Schall,et al.  Overcoming hurdles in developing successful drugs targeting chemokine receptors , 2011, Nature Reviews Immunology.

[11]  S. Sakaguchi,et al.  Human FoxP3+CD4+ regulatory T cells: their knowns and unknowns , 2011, Immunology and cell biology.

[12]  D. Campbell,et al.  Phenotypical and functional specialization of FOXP3+ regulatory T cells , 2011, Nature Reviews Immunology.

[13]  C. Loddenkemper,et al.  Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. , 2010, Cancer research.

[14]  M. Smyth,et al.  Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth , 2010 .

[15]  X. Chen,et al.  Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. , 2010, Lung cancer.

[16]  C. Figdor,et al.  Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.

[17]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.

[18]  K. Ohshima,et al.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Koch,et al.  Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. , 2009, The Journal of clinical investigation.

[20]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[21]  S. Bromley,et al.  Orchestrating the orchestrators: chemokines in control of T cell traffic , 2008, Nature Immunology.

[22]  D. Speiser,et al.  Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood , 2008, Cancer Immunology, Immunotherapy.

[23]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[24]  H. Sakurai,et al.  RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4 , 2006, Clinical & Experimental Metastasis.

[25]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Rosenberg,et al.  Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma , 2005, Journal of immunotherapy.

[27]  T. Nomura,et al.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.

[28]  L. Old,et al.  CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.

[29]  K. Buetow,et al.  Chromatin Remodeling Factors and BRM/BRG1 Expression as Prognostic Indicators in Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[30]  K. Shitara,et al.  Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma , 2004, Cancer Research.

[31]  P. Panina-Bordignon,et al.  Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells , 2004, European journal of immunology.

[32]  Yuji Kikuchi,et al.  A novel optical assay system for the quantitative measurement of chemotaxis. , 2003, Journal of immunological methods.

[33]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[34]  S. Yamagiwa,et al.  A Role for TGF-β in the Generation and Expansion of CD4+CD25+ Regulatory T Cells from Human Peripheral Blood1 , 2001, The Journal of Immunology.

[35]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[36]  P. Gray,et al.  Macrophage-derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4* , 1998, The Journal of Biological Chemistry.

[37]  O. Yoshie,et al.  The T Cell-directed CC Chemokine TARC Is a Highly Specific Biological Ligand for CC Chemokine Receptor 4* , 1997, The Journal of Biological Chemistry.

[38]  R. Horuk,et al.  Chemokine receptor antagonists: overcoming developmental hurdles , 2009, Nature Reviews Drug Discovery.

[39]  E. Shevach,et al.  Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.

[40]  S. Yamagiwa,et al.  A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. , 2001, Journal of immunology.